| Item type |
文献 / Documents(1) |
| 公開日 |
2023-02-16 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1093/ehjcvp/pvac059 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1093/ehjcvp/pvac059 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial |
|
言語 |
en |
| タイトル別表記 |
|
|
その他のタイトル |
Effect of ipragliflozin on carotid intima-media thickness in type 2 diabetes patients |
|
言語 |
en |
| 著者 |
タナカ, アツシ
佐田, 政隆
オカダ, ヨウスケ
テラガワ, ヒロキ
エグチ, カズオ
島袋, 充生
タグチ, イサオ
マツナガ, カズオ
カンザキ, ユミコ
ヨシダ, ヒサコ
イシヅ, トモコ
ウエダ, シンイチロウ
キタカゼ, マサフミ
ムロハラ, トヨアキ
ノデ, コウイチ
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Aims
To examine the effects of a 24-month treatment with ipragliflozin on carotid intima-media thickness (IMT) in type 2 diabetes patients.
Methods and results
In this multicenter, prospective, randomized, open-label, and blinded-endpoint investigator-initiated clinical trial, adults with type 2 diabetes and haemoglobin A1C (HbA1c) of 6.0–10.0% (42–86 mmol/mol) were randomized equally to ipragliflozin (50 mg daily) and non-sodium-glucose cotransporter-2 (SGLT2) inhibitor use of standard-care (control group) for type 2 diabetes and were followed-up to 24 months. The primary endpoint was the change in mean common carotid artery IMT (CCA-IMT) from baseline to 24 months. A total of 482 patients were equally allocated to the ipragliflozin (N = 241) and control (N = 241) groups, and 464 patients (median age 68 years, female 31.7%, median type 2 diabetes duration 8 years, median HbA1c 7.3%) were included in the analyses. For the primary endpoint, the changes in the mean CCA-IMT from baseline to 24 months were 0.0013 [95% confidence interval (CI), −0.0155–0.0182] mm and 0.0015 (95% CI, −0.0155–0.0184) mm in the ipragliflozin and control groups, respectively, with an estimated group difference (ipragliflozin-control) of −0.0001 mm (95% CI, −0.0191–0.0189; P = 0.989). A group difference in HbA1c change at 24 months was also non-significant between the treatment groups [−0.1% (95% CI, −0.2–0.1); P = 0.359].
Conclusion
Twenty-four months of ipragliflozin treatment did not affect carotid IMT status in patients with type 2 diabetes recruited in the PROTECT study, relative to the non-SGLT2 inhibitor-use standard care for type 2 diabetes. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Atherosclerosis |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Carotid intima-media thickness |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Ipragliflozin |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Type 2 diabetes |
| 書誌情報 |
en : European Heart Journal - Cardiovascular Pharmacotherapy
巻 9,
号 2,
p. 165-172,
発行日 2022-10-29
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
20556845 |
| 出版者 |
|
|
出版者 |
Oxford University Press |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
European Society of Cardiology |
|
言語 |
en |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| EID |
|
|
識別子 |
394010 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
ehjcvp_9_2_165.pdf (609 KB)
.png)
